Assesses 5 year risk of treatment failure based on clinical factors.
With changing treatment patterns, there is a large variation on how to treat different risk groups. Low risk patients seem to do well with many treatment modalities. Intermediate risk patients are a very variable group, where further understanding of risk of cancer “beyond the gland” may be necessary to guide treatment. High risk groups often do best with a multimodal treatment approach.